Back |
home / stock / cvac / cvac message board
Subject | By | Source | When |
---|---|---|---|
CureVac is truly a one-stop shop for mRNA | XenaLives | investorshub | 09/26/2021 11:46:04 AM |
PIPELINE See where were heading | XenaLives | investorshub | 09/26/2021 11:45:00 AM |
This is not a COVID stock - applications | XenaLives | investorshub | 09/26/2021 11:43:19 AM |
The difference is in the MOA of the | XenaLives | investorshub | 09/26/2021 11:30:27 AM |
mRNA tech is valid - It seems that | XenaLives | investorshub | 09/26/2021 11:29:14 AM |
Telomeres and cancer: https://www.nature.com/articles/nrm.2016.171 | XenaLives | investorshub | 09/26/2021 11:26:32 AM |
CureVac NV ($CVAC) | mick | investorshub | 09/22/2021 11:22:21 PM |
CureVac NV ($CVAC) | mick | investorshub | 08/14/2021 3:57:49 PM |
CureVac NV ($CVAC) | mick | investorshub | 07/11/2021 2:52:34 AM |
i got some @ $43 'CureVac B.V. ($CVAC)' | mick | investorshub | 06/19/2021 11:04:26 PM |
$CVAC-this was a good falling knife trade ;) | Nebuchadnezzar | investorshub | 06/19/2021 4:31:28 PM |
great thank you for sharing i did more | mick | investorshub | 06/17/2021 12:32:41 AM |
I'm lucky I got in early in October | Go Hawks13 | investorshub | 06/17/2021 12:27:19 AM |
znewcar1: CVAC 22% v1,5M c105.17 f177M H106.5 | znewcar1 | investorshangout | 11/30/2020 10:03:16 PM |
News, Short Squeeze, Breakout and More Instantly...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine ca...